治疗前血红蛋白水平作为局部晚期头颈部鳞状细胞癌患者的预后因素
Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma.
作者信息
Melo-Alvim Cecília, Miguel-Semedo Patrícia, Paiva Rita Silva, Lobo-Martins Soraia, Luna-Pais Helena, Costa Ana Lúcia, Santos Ana Rita, Florindo André, Vasconcelos Ana Luísa, Abrunhosa-Branquinho André N, Palmela Paulo, Fernandes Leonor, Presa Dolores Lopez, Costa Luís, Ribeiro Leonor
机构信息
Medical Oncology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon 1649-035, Portugal.
Otorhinolaryngology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon 1649-035, Portugal.
出版信息
Rep Pract Oncol Radiother. 2020 Sep-Oct;25(5):768-774. doi: 10.1016/j.rpor.2020.07.002. Epub 2020 Jul 28.
AIM
Evaluate pretreatment hemoglobin values as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy.
BACKGROUND
Anemia is one of the most prevalent laboratory abnormalities in oncological disease. It leads to a decrease in cellular oxygen supply, altering radiosensitivity of tumor cells and compromising therapeutic outcomes.
MATERIALS AND METHODS
Retrospective evaluation of patients with HNSCC treated with cCRT. Primary and secondary endpoint was to evaluate the correlation of Hb levels (≥12.5 g/dL or <12.5 g/dL) at the beginning of cCRT with overall survival (OS) and progression-free survival (PFS), respectively.
RESULTS
A total of 108 patients were identified. With a median follow-up of 16.10 months median OS was 59.70 months for Hb ≥12.5 g/dL vs. 14.13 months for Hb <12.5 g/dL ( = 0.004). PFS was 12.29 months for Hb ≥12.5 g/dL and 1.68 months for Hb <12.5 g/dL ( = 0.016).
CONCLUSIONS
In this analysis, Hb ≥12.5 g/dL correlated with significantly better OS and PFS. Further studies are needed to validate these findings.
目的
评估在接受同步放化疗的局部晚期头颈部鳞状细胞癌患者中，治疗前血红蛋白值作为预后因素的情况。
背景
贫血是肿瘤疾病中最常见的实验室异常之一。它会导致细胞氧供应减少，改变肿瘤细胞的放射敏感性并影响治疗效果。
材料与方法
对接受同步放化疗的头颈部鳞状细胞癌患者进行回顾性评估。主要和次要终点分别是评估同步放化疗开始时血红蛋白水平（≥12.5 g/dL或<12.5 g/dL）与总生存期（OS）和无进展生存期（PFS）的相关性。
结果
共纳入108例患者。中位随访16.10个月，血红蛋白≥12.5 g/dL组的中位总生存期为59.70个月，而血红蛋白<12.5 g/dL组为14.13个月（P = 0.004）。血红蛋白≥12.5 g/dL组的无进展生存期为12.29个月，血红蛋白<12.5 g/dL组为1.68个月（P = 0.016）。
结论
在本分析中，血红蛋白≥12.5 g/dL与显著更好的总生存期和无进展生存期相关。需要进一步研究来验证这些发现。
Zotero 插件